Fate Therapeutics (FATE) Financials: History & Chart

Fate Therapeutics, Inc.(FATE)

Biotechnology · San Diego, CA

$2.29-0.14 (-5.76%)

Delayed quote: Oct 6, 2026, 4:00 PM EDT

About Fate Therapeutics, Inc.

Fate Therapeutics, Inc. is a clinical-stage biopharmaceutical firm dedicated to creating advanced, programmed cellular immunotherapies. These innovative treatments are designed to combat cancer and various immune disorders across the globe. A significant portion of its development pipeline concentrates on NK- and T-cell immuno-oncology programs. Key candidates include FT516, which targets acute myeloid leukemia (AML), B-cell lymphoma, and advanced solid tumors; FT596 for B-cell lymphoma and chronic lymphocytic leukemia; FT538, addressing AML and multiple myeloma; FT576, also focused on multiple myeloma; FT819, aimed at both hematologic malignancies and solid tumors; FT536, another program for solid tumors; and FT500, intended for advanced solid tumors. The company also actively engages in strategic collaborations to advance its research and development. It holds an agreement with Ono Pharmaceutical Co. Ltd. for the joint development and commercialization of two novel, "off-the-shelf" iPSC-derived CAR T-cell therapies. Furthermore, Fate Therapeutics maintains a research collaboration and licensing deal with Juno Therapeutics, Inc., focusing on identifying small molecule modulators that can enhance the therapeutic efficacy of genetically engineered T-cell immunotherapies. A separate collaboration and option agreement exists with Janssen Biotech, Inc. Established in 2007, Fate Therapeutics, Inc. is based in San Diego, California.

San Diego, CA

161 employees

www.fatetherapeutics.com

Healthcare / Biotechnology

Sector: Healthcare
Industry: Biotechnology
CEO: Bahram Valamehr

View full financials

Financials

SEC Filings

Quarterly Income Statement (USD)

Swipe horizontally to review earlier periods. The line-item column stays pinned.

Quarterly Report	TTM	Quarter ended Jun 2026	Quarter ended Mar 2026	Quarter ended Dec 2025	Quarter ended Sep 2025	Quarter ended Jun 2025	Quarter ended Mar 2025	Quarter ended Dec 2024	Quarter ended Sep 2024
Revenue	6.49M	2.08M	1.30M	1.37M	1.74M	1.91M	1.63M	1.86M	3.07M
Cost of Goods Sold	28.76M	0.00	2.92M	0.00	25.84M	3.82M	29.14M	17.14M	34.65M
Gross Profit	-22.27M	2.08M	-1.62M	1.37M	-24.10M	-1.91M	-27.51M	-15.28M	-31.58M
Gross Profit Margin	-343.0%	100.0%	-124.6%	100.0%	-1384.1%	-100.4%	-1688.6%	-821.5%	-1027.2%
Total Operating Expenses	111.33M	33.22M	31.38M	36.09M	10.64M	35.05M	13.77M	46.47M	20.80M
Research & Development	97.44M	24.39M	21.79M	25.43M	25.84M	27.43M	29.14M	33.61M	34.65M
Selling, General & Administrative	39.73M	8.83M	9.60M	10.66M	10.64M	11.45M	13.77M	31.73M	20.80M
Operating Income (EBIT)	-133.59M	-31.13M	-33.00M	-34.72M	-34.73M	-36.97M	-41.28M	-61.75M	-52.38M
Operating Margin	-2058.1%	-1495.4%	-2540.4%	-2536.2%	-1995.1%	-1938.5%	-2534.1%	-3319.8%	-1703.9%
Income Before Tax (EBT)	-126.00M	-30.16M	-31.21M	-32.37M	-32.25M	-34.07M	-37.62M	-52.15M	-47.68M
Interest Income	8.22M	1.55M	1.87M	2.22M	2.58M	2.92M	3.34M	3.87M	4.44M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Other Income/Expense	7.59M	975K	1.79M	2.35M	2.48M	2.90M	3.66M	9.60M	4.70M
Net Income	-126.00M	-30.16M	-31.21M	-32.37M	-32.25M	-34.07M	-37.62M	-52.15M	-47.68M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-1941.1%	-1448.6%	-2402.8%	-2364.8%	-1852.4%	-1786.6%	-2309.5%	-2803.9%	-1551.0%
EBITDA	-121.60M	-28.35M	-30.08M	-31.66M	-31.51M	-33.69M	-37.95M	-56.94M	-47.77M
EBITDA Margin	-1873.4%	-1361.9%	-2315.8%	-2312.5%	-1809.8%	-1766.6%	-2329.5%	-3061.0%	-1554.0%
Depreciation & Amortization	11.99M	2.78M	2.92M	3.06M	3.23M	3.28M	3.33M	4.81M	4.61M
EPS Basic	-1.05	-0.25	-0.26	-0.27	-0.27	-0.29	-0.32	-0.44	-0.40
EPS Diluted	-1.05	-0.25	-0.26	-0.27	-0.27	-0.29	-0.32	-0.44	-0.40
Weighted Average Basic Shares	120.40M	120.40M	120.03M	118.79M	119.00M	118.53M	118.38M	117.79M	117.77M
Weighted Average Diluted Shares	120.40M	120.40M	120.03M	118.79M	119.00M	118.53M	118.38M	117.79M	117.77M

Annual Income Statement (USD)

Swipe horizontally to review earlier years. The line-item column stays pinned.

Annual Report	12/31/2025	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018
Revenue	6.65M	13.63M	63.53M	96.30M	55.85M	31.43M	10.68M	4.74M
Cost of Goods Sold	12.90M	118.53M	157.19M	13.76M	5.85M	125.62M	0.00	56.02M
Gross Profit	-6.25M	-104.90M	-93.65M	82.54M	50.00M	-94.19M	10.68M	-51.28M
Gross Profit Margin	-94.1%	-769.6%	-147.4%	85.7%	89.5%	-299.6%	100.0%	-1081.9%
Total Operating Expenses	141.45M	105.38M	96.86M	390.93M	266.99M	33.90M	111.41M	71.83M
Research & Development	107.83M	135.00M	172.60M	320.45M	215.52M	125.62M	87.77M	56.02M
Selling, General & Administrative	46.52M	90.64M	96.86M	84.23M	57.32M	33.90M	23.64M	15.81M
Operating Income (EBIT)	-147.70M	-210.28M	-190.51M	-308.39M	-216.99M	-128.09M	-100.73M	-67.09M
Operating Margin	-2222.4%	-1542.6%	-299.9%	-320.2%	-388.6%	-407.5%	-943.1%	-1415.4%
Income Before Tax (EBT)	-136.31M	-186.26M	-160.93M	-281.72M	-212.15M	-173.39M	-98.15M	-66.60M
Interest Income	11.05M	17.29M	17.19M	5.84M	1.31M	2.40M	4.33M	2.19M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	1.75M	1.70M
Other Income/Expense	11.39M	24.01M	29.58M	26.66M	4.84M	-45.30M	2.58M	494K
Net Income	-136.31M	-186.26M	-160.93M	-281.72M	-212.15M	-173.39M	-98.15M	-66.60M
Income Tax Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Net Profit Margin	-2051.1%	-1366.5%	-253.3%	-292.5%	-379.9%	-551.6%	-919.0%	-1405.0%
EBITDA	-138.41M	-191.31M	-172.23M	-294.63M	-211.14M	-125.00M	-98.53M	-65.89M
EBITDA Margin	-2082.6%	-1403.5%	-271.1%	-305.9%	-378.1%	-397.7%	-922.6%	-1390.0%
Depreciation & Amortization	9.29M	18.96M	18.28M	13.76M	5.85M	3.09M	2.19M	1.20M
EPS Basic	-1.15	-1.64	-1.64	-2.91	-2.24	-2.10	-1.43	-1.19
EPS Diluted	-1.15	-1.64	-1.64	-2.91	-2.24	-2.10	-1.43	-1.19
Weighted Average Basic Shares	118.79M	113.69M	98.41M	96.83M	94.75M	82.39M	68.19M	56.20M
Weighted Average Diluted Shares	118.79M	113.69M	98.41M	96.83M	94.75M	82.39M	68.19M	56.20M

Values are displayed in USD. Negative numbers shown in red.

Values are displayed in USD. Negative numbers are shown in red.